Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection

Makito Miyake, Shanti Ross, Adrienne Lawton, Myron Chang, Yunfeng Dai, Lourdes Mengual, Antonio Alcaraz, Evan Gomes Giacoia, Steven Goodison, Charles J. Rosser

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: In this study, we further investigated the association of two biomarkers, CCL18 and A1AT, with bladder cancer (BCa) and evaluated the influence of potentially confounding factors in an experimental model. Methods. In a cohort of 308 subjects (102 with BCa), urinary concentrations of CCL18 and A1AT were assessed by enzyme-linked immunosorbent assay (ELISA). In an experimental model, benign or cancerous cells, in addition to blood, were added to urines from healthy controls and analyzed by ELISA. Lastly, immunohistochemical staining for CCL18 and A1AT in human bladder tumors was performed. Results: Median urinary protein concentrations of CCL18 (52.84 pg/ml vs. 11.13 pg/ml, p < 0.0001) and A1AT (606.4 ng/ml vs. 120.0 ng/ml, p < 0.0001) were significantly elevated in BCa subjects compared to controls. Furthermore, the addition of whole blood to pooled normal urine resulted in a significant increase in both CCL18 and A1AT. IHC staining of bladder tumors revealed CCL18 immunoreactivity in inflammatory cells only, and there was no significant increase in these immunoreactive cells within benign and cancerous tissue and no association with BCa grade nor stage was noted. A1AT immunoreactivity was observed in the cytoplasm of epithelia cells and intensity of immunostaining increased with tumor grade, but not tumor stage. Conclusions: Further development of A1AT as a diagnostic biomarker for BCa is warranted.

Original languageEnglish (US)
Article number42
JournalBMC Urology
Volume13
DOIs
StatePublished - Sep 9 2013
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Theoretical Models
Enzyme-Linked Immunosorbent Assay
Urine
Staining and Labeling
Neoplasms
Cytoplasm
Epithelium
Proteins

Keywords

  • Biomarkers
  • Bladder cancer
  • Specificity
  • Urine

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

Miyake, M., Ross, S., Lawton, A., Chang, M., Dai, Y., Mengual, L., ... Rosser, C. J. (2013). Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. BMC Urology, 13, [42]. https://doi.org/10.1186/1471-2490-13-42

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. / Miyake, Makito; Ross, Shanti; Lawton, Adrienne; Chang, Myron; Dai, Yunfeng; Mengual, Lourdes; Alcaraz, Antonio; Giacoia, Evan Gomes; Goodison, Steven; Rosser, Charles J.

In: BMC Urology, Vol. 13, 42, 09.09.2013.

Research output: Contribution to journalArticle

Miyake, M, Ross, S, Lawton, A, Chang, M, Dai, Y, Mengual, L, Alcaraz, A, Giacoia, EG, Goodison, S & Rosser, CJ 2013, 'Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection', BMC Urology, vol. 13, 42. https://doi.org/10.1186/1471-2490-13-42
Miyake, Makito ; Ross, Shanti ; Lawton, Adrienne ; Chang, Myron ; Dai, Yunfeng ; Mengual, Lourdes ; Alcaraz, Antonio ; Giacoia, Evan Gomes ; Goodison, Steven ; Rosser, Charles J. / Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection. In: BMC Urology. 2013 ; Vol. 13.
@article{5efa5e9c01bf4c37bacedbdb02a8db2f,
title = "Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection",
abstract = "Background: In this study, we further investigated the association of two biomarkers, CCL18 and A1AT, with bladder cancer (BCa) and evaluated the influence of potentially confounding factors in an experimental model. Methods. In a cohort of 308 subjects (102 with BCa), urinary concentrations of CCL18 and A1AT were assessed by enzyme-linked immunosorbent assay (ELISA). In an experimental model, benign or cancerous cells, in addition to blood, were added to urines from healthy controls and analyzed by ELISA. Lastly, immunohistochemical staining for CCL18 and A1AT in human bladder tumors was performed. Results: Median urinary protein concentrations of CCL18 (52.84 pg/ml vs. 11.13 pg/ml, p < 0.0001) and A1AT (606.4 ng/ml vs. 120.0 ng/ml, p < 0.0001) were significantly elevated in BCa subjects compared to controls. Furthermore, the addition of whole blood to pooled normal urine resulted in a significant increase in both CCL18 and A1AT. IHC staining of bladder tumors revealed CCL18 immunoreactivity in inflammatory cells only, and there was no significant increase in these immunoreactive cells within benign and cancerous tissue and no association with BCa grade nor stage was noted. A1AT immunoreactivity was observed in the cytoplasm of epithelia cells and intensity of immunostaining increased with tumor grade, but not tumor stage. Conclusions: Further development of A1AT as a diagnostic biomarker for BCa is warranted.",
keywords = "Biomarkers, Bladder cancer, Specificity, Urine",
author = "Makito Miyake and Shanti Ross and Adrienne Lawton and Myron Chang and Yunfeng Dai and Lourdes Mengual and Antonio Alcaraz and Giacoia, {Evan Gomes} and Steven Goodison and Rosser, {Charles J.}",
year = "2013",
month = "9",
day = "9",
doi = "10.1186/1471-2490-13-42",
language = "English (US)",
volume = "13",
journal = "BMC Urology",
issn = "1471-2490",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection

AU - Miyake, Makito

AU - Ross, Shanti

AU - Lawton, Adrienne

AU - Chang, Myron

AU - Dai, Yunfeng

AU - Mengual, Lourdes

AU - Alcaraz, Antonio

AU - Giacoia, Evan Gomes

AU - Goodison, Steven

AU - Rosser, Charles J.

PY - 2013/9/9

Y1 - 2013/9/9

N2 - Background: In this study, we further investigated the association of two biomarkers, CCL18 and A1AT, with bladder cancer (BCa) and evaluated the influence of potentially confounding factors in an experimental model. Methods. In a cohort of 308 subjects (102 with BCa), urinary concentrations of CCL18 and A1AT were assessed by enzyme-linked immunosorbent assay (ELISA). In an experimental model, benign or cancerous cells, in addition to blood, were added to urines from healthy controls and analyzed by ELISA. Lastly, immunohistochemical staining for CCL18 and A1AT in human bladder tumors was performed. Results: Median urinary protein concentrations of CCL18 (52.84 pg/ml vs. 11.13 pg/ml, p < 0.0001) and A1AT (606.4 ng/ml vs. 120.0 ng/ml, p < 0.0001) were significantly elevated in BCa subjects compared to controls. Furthermore, the addition of whole blood to pooled normal urine resulted in a significant increase in both CCL18 and A1AT. IHC staining of bladder tumors revealed CCL18 immunoreactivity in inflammatory cells only, and there was no significant increase in these immunoreactive cells within benign and cancerous tissue and no association with BCa grade nor stage was noted. A1AT immunoreactivity was observed in the cytoplasm of epithelia cells and intensity of immunostaining increased with tumor grade, but not tumor stage. Conclusions: Further development of A1AT as a diagnostic biomarker for BCa is warranted.

AB - Background: In this study, we further investigated the association of two biomarkers, CCL18 and A1AT, with bladder cancer (BCa) and evaluated the influence of potentially confounding factors in an experimental model. Methods. In a cohort of 308 subjects (102 with BCa), urinary concentrations of CCL18 and A1AT were assessed by enzyme-linked immunosorbent assay (ELISA). In an experimental model, benign or cancerous cells, in addition to blood, were added to urines from healthy controls and analyzed by ELISA. Lastly, immunohistochemical staining for CCL18 and A1AT in human bladder tumors was performed. Results: Median urinary protein concentrations of CCL18 (52.84 pg/ml vs. 11.13 pg/ml, p < 0.0001) and A1AT (606.4 ng/ml vs. 120.0 ng/ml, p < 0.0001) were significantly elevated in BCa subjects compared to controls. Furthermore, the addition of whole blood to pooled normal urine resulted in a significant increase in both CCL18 and A1AT. IHC staining of bladder tumors revealed CCL18 immunoreactivity in inflammatory cells only, and there was no significant increase in these immunoreactive cells within benign and cancerous tissue and no association with BCa grade nor stage was noted. A1AT immunoreactivity was observed in the cytoplasm of epithelia cells and intensity of immunostaining increased with tumor grade, but not tumor stage. Conclusions: Further development of A1AT as a diagnostic biomarker for BCa is warranted.

KW - Biomarkers

KW - Bladder cancer

KW - Specificity

KW - Urine

UR - http://www.scopus.com/inward/record.url?scp=84883457372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883457372&partnerID=8YFLogxK

U2 - 10.1186/1471-2490-13-42

DO - 10.1186/1471-2490-13-42

M3 - Article

C2 - 24011266

AN - SCOPUS:84883457372

VL - 13

JO - BMC Urology

JF - BMC Urology

SN - 1471-2490

M1 - 42

ER -